Tempest Therapeutics Inc

NASDAQ TPST

Download Data

Tempest Therapeutics Inc Operating Income Per Share 2 year CAGR for the quarter ending March 31, 2024: -43.88%

Tempest Therapeutics Inc Operating Income Per Share 2 year CAGR is -43.88% for the quarter ending March 31, 2024, a -181.83% change year over year. Operating income per share represents the amount of operating income generated by a company per outstanding share. It is calculated by dividing the operating income by the weighted average number of basic shares outstanding. This metric provides insights into the company's profitability from its core operations on a per-share basis. It is useful for evaluating the company's operational performance and comparing it with other companies on a per-share basis. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Tempest Therapeutics Inc Operating Income Per Share for the quarter ending March 31, 2023 was -0.55, a 51.63% change year over year.
  • Tempest Therapeutics Inc Operating Income Per Share for the quarter ending March 31, 2022 was -1.14, a -47.36% change year over year.
  • Tempest Therapeutics Inc Operating Income Per Share for the quarter ending March 31, 2021 was -0.77, a 94.11% change year over year.
  • Tempest Therapeutics Inc Operating Income Per Share for the quarter ending March 31, 2020 was -13.11, a -28.54% change year over year.
NASDAQ: TPST

Tempest Therapeutics Inc

CEO Mr. Stephen R. Brady J.D., LLM
IPO Date Nov. 12, 2012
Location United States
Headquarters 7000 Shoreline Court, South San Francisco, CA, United States, 94080
Employees 17
Sector Healthcare
Industry Biotechnology
Description

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Similar companies

CGEM

Cullinan Oncology LLC

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

THRX

Theseus Pharmaceuticals Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email